The addition of valsartan to optimized therapy in a cohort of Japanese patients with coronary heart disease and hypertension provides. Description: RETRACTION: The editors of the European Heart Journal have retracted the article reporting data/results of the Jikei Heart Study. The Lancet has formally retracted the Jikei Heart Study paper, originally published in The retraction had been widely anticipated for more.
|Published (Last):||2 October 2014|
|PDF File Size:||3.78 Mb|
|ePub File Size:||8.95 Mb|
|Price:||Free* [*Free Regsitration Required]|
It is therefore important to verify that the results of these studies are also valid for Japanese patients. If the CNS journals did the right thing, we would have seen several more retractions recently McGill etc. Dr Azam also told us: Although we were initially satisfied with their response, in we published a letter from Dr Yui reporting further concerns.
Our attempts to obtain studu response from Mr Shirahashi were hindered by his recent retirement from Novartis, but the Global Head of Medical Affairs, Dr Usman Azam, did share with The Lancet that Mr Shirahashi had been employed by Novartis throughout the period of the trial and its publication. Your email address will not be published. Sum and substance in the Jikei Heart Study.
Taken together, these findings indicate that there is now sufficient doubt as to the integrity of the Jikei Heart Study and the obfuscation over affiliation of the study statistician for The Lancet formally to retract the paper from the scientific record.
Eur Heart J ; This site uses Akismet to reduce spam. Learn how your comment data is processed.
Lancet retracts Jikei Heart Study of valsartan following investigation – Retraction Watch
Effects of valsartan hearr morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: Too much skin in the game, as duplications force retraction of psoriasis paper. Given this finding, we now wish to retract the Jikei Heart Study on the grounds that we no longer have confidence in the published results.
We became aware of this development on April 29,and on May 2 we wrote to Jikei University asking for details of the investigation and requesting that we be kept informed. Sorry, your blog cannot share posts by email.
Lancet retracts Jikei Heart Study of valsartan following investigation
Matsubara is not an author on the Jikei study. Papers on potential cancer drugs retracted for image manipulation.
But we soon became aware that there was concern in Japan about the trial. The report also comments on the affiliation of the person entrusted with the statistical analysis, Nobuo Shirahashi. The primary endpoint will be the onset of any cardiovascular event. Sub-studies will explore the effect in jikfi with diabetes mellitus, hyperlipidemia and the effects of combination of drugs.
There should be some accountability here by executuves jkei Novartis. In October,we received correspondence expressing concern about the similarity of the standard deviations of the mean blood pressure measurements in the two studies, and we invited the authors to comment.
Another outrageous and potentiall quite dangerous violoation of medical, scientific, and human ethics by Big Pharma trying to sell their products. Several recent clinical trials have demonstrated that angiotensin II receptor blockers ARBs have cardiovascular as well as renal protective effects.
We wrote again on June 4 and June 19 asking when the investigation might be completed. Concerns about the Jikei Heart Study. Accumulated sales of Diovan in Japan reaches 12 billion dollars US! Jilei follow-up period will be three years. He held the position until An investigating committee headed by Professor Hashimoto from Jikei University was established.
Asian patients including Japanese were under-represented in these trials, however, and no large-scale clinical trials of ARBs have yet been performed in Japan.